Category Press Releases

Poxel Announces Drawdown of Additional Tranche D PDR Bonds Under Continuation Plan

Poxel Announces Drawdown of Additional Tranche D PDR Bonds Under Continuation Plan POXEL SA, a biopharmaceutical firm specializing in innovative therapies for serious chronic diseases with metabolic origins, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, has announced a…

Read MorePoxel Announces Drawdown of Additional Tranche D PDR Bonds Under Continuation Plan

Element Science Recognized on Fast Company’s 2026 List of the World’s Most Innovative Companies

Element Science Earns Spot on Fast Company’s 2026 List of the World’s Most Innovative Companies Element Science has earned a place on Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026, a recognition that highlights organizations driving…

Read MoreElement Science Recognized on Fast Company’s 2026 List of the World’s Most Innovative Companies

U.S. FDA Approves Updated Label for ADSTILADRIN® to Enable Faster Thawing Time

U.S. Food and Drug Administration Approves Updated Label to Enable Faster Thawing of ADSTILADRIN® (nadofaragene firadenovec-vncg) Ferring Pharmaceuticals has announced that the U.S. Food and Drug Administration has approved an important label update for ADSTILADRIN, introducing a faster and more…

Read MoreU.S. FDA Approves Updated Label for ADSTILADRIN® to Enable Faster Thawing Time

Alnylam Expands Innovation in ATTR-CM Management with Viz.ai Partnership and American Heart Association Collaboration

Alnylam Drives Innovation in ATTR-CM Care Through Strategic Collaboration with Viz.ai and Ongoing Support for the American Heart Association Alnylam Pharmaceuticals is spearheading a comprehensive, system-wide initiative aimed at transforming the early detection and management of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM),…

Read MoreAlnylam Expands Innovation in ATTR-CM Management with Viz.ai Partnership and American Heart Association Collaboration

Dupixent Approved in Japan as the First Targeted Therapy for Adults with Bullous Pemphigoid (BP)

Dupixent Approved in Japan as the First Targeted Therapy for Adults with Bullous Pemphigoid Regeneron Pharmaceuticals and Sanofi have announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted approval for Dupixent as a treatment for adults suffering…

Read MoreDupixent Approved in Japan as the First Targeted Therapy for Adults with Bullous Pemphigoid (BP)

Pfizer and Valneva Report Strong Phase 3 VALOR Trial Results for Lyme Disease Vaccine Candidate Demonstrating High Efficacy

Pfizer and Valneva Report Positive Phase 3 VALOR Results Showing High Efficacy for Lyme Disease Vaccine Candidate Pfizer Inc. and Valneva SE have announced encouraging topline findings from the pivotal Phase 3 VALOR clinical trial evaluating their investigational Lyme disease…

Read MorePfizer and Valneva Report Strong Phase 3 VALOR Trial Results for Lyme Disease Vaccine Candidate Demonstrating High Efficacy

Curi Bio and Battelle Partner to Advance Neuromuscular Pharmacology Innovations

Curi Bio and Battelle Forge Strategic Alliance to Advance New Approach Methods in Neuromuscular Pharmacology Curi Bio, a recognized leader in the development of human-relevant three-dimensional (3D) tissue platforms, has entered into a strategic partnership with Battelle, the world’s largest…

Read MoreCuri Bio and Battelle Partner to Advance Neuromuscular Pharmacology Innovations

Newron to Showcase Latest Advances at the 2026 Schizophrenia International Research Society Annual Congress 2026

Newron Showcases Latest Research at the 2026 Schizophrenia International Research Society Annual Congress 2026 Newron Pharmaceuticals S.p.A., a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for disorders affecting the central and peripheral nervous systems, has announced its active participation…

Read MoreNewron to Showcase Latest Advances at the 2026 Schizophrenia International Research Society Annual Congress 2026

Novo Nordisk Secures U.S. Approval for Wegovy HD (7.2 mg), Delivering 20.7% Average Weight Reduction

Novo Nordisk A/S: Wegovy® HD (7.2 mg) gains US approval, delivering 20.7% average weight reduction Novo Nordisk has reached another major milestone in the treatment of obesity, announcing that the U.S. Food and Drug Administration (FDA) has granted approval for…

Read MoreNovo Nordisk Secures U.S. Approval for Wegovy HD (7.2 mg), Delivering 20.7% Average Weight Reduction